BIZCENTER USA Launches Coworking Facility in Orlando With Plans for Nationwide Franchise
14.10.2019 07:01:00 EEST | Business Wire | Press release
Multimedia, Inc. (www.multimediausa.com) starts today the operations of BIZCENTER USA LLC, its affiliate for shared workspaces and virtual offices. Located on a fully owned 4,400 sq. ft. area in one of the most strategic regions of Orlando, Florida, BIZCENTER USA is offering brand-new state of the art executive suites in a facility with upscale conference rooms, reception, luxury lounge, and kitchen.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191013005018/en/
Founded in Orlando in 1991, Multimedia is a leading marketing and communications company, highly recognized worldwide for its professional integrity, serving advertising agencies, direct clients and media outlets across all continents. According to Fernando Mariano, president of both companies, the creation of BIZCENTER USA fulfills the needs for a stylish shared workspace and virtual office facility in Southwest Orlando.
“Multimedia has strong ties with the Orlando community and we are always looking to respond to the needs of the local residents as well as to the needs of our clients throughout the U.S. and the world. The start of BIZCENTER USA in Orlando is just the first step for us to create a coworking franchise operating coast-to-coast in America under high level standards of professional support for our clients,” said Mariano.
BIZCENTER USA offers 23 private executive suites for 1, 2 and 3 professionals. All suites have contemporary furnishings, including a large desk with drawers, wall cabinet, ergonomic chair, phone, and hand painted art on wall. Two internet connections – one with 1 Gb – from different providers guarantee the best wired and wireless experience. Floor to ceiling glass walls, along with sound proof solid walls and ceilings contribute for a quiet and productive ambiance.
Two conference rooms equipped with advanced 4K 65" HDR TVs, dry erase boards and full conference call systems are available. An ample reception, lounge and kitchen complete a premium coworking atmosphere.
The virtual office program, among other advantages, provides a prestigious business address for home office executives, protecting the privacy of their residence. The same program is a must for clients that do not live in Orlando and need an address to receive mail or to register a company for any official or banking needs. Clients may opt for mailboxes only. BIZCENTER USA also offers daily rentals of conference rooms and executive suites.
The attached presentation carries all details. Additional information please visit www.bizcenterusa.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191013005018/en/
Contact information
BIZCENTER USA LLC
Karen Marin, +1-407-634-6000 Ext. 221
karen@bizcenterusa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 09:30:00 EEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis4.8.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803530661/en/ 4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee osteoarthritis INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial conducted across Europe, the United States and Canada
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 16:30:00 EEST | Press release
ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential challenges facing modern data systems, as AI reshapes the demands placed on all data-intensive workloads. “At ClickHouse, we are interested in finding new and inno
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 16:30:00 EEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom